Basic information Safety Supplier Related

Xipamide

Basic information Safety Supplier Related

Xipamide Basic information

Product Name:
Xipamide
Synonyms:
  • 4-Chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulphamoylbenzamide 95+%
  • Xipamide
  • XIPAMIDE (IN HOUSE)
  • 4-Chloro-5-sulfamoyl-2',6'-salicyloxylidide
  • 5-(Aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxybenzamide
  • Benzamide,5-(aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-
  • 4-Chloro-2-hydroxy-N-(2,6-dimethylphenyl)-5-sulfamoylbenzamide
  • Aquaphor(diuretic)
CAS:
14293-44-8
MF:
C15H15ClN2O4S
MW:
354.81
EINECS:
238-216-4
Product Categories:
  • Xipamide
  • APIs
  • Aromatics
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Sulfur & Selenium Compounds
Mol File:
14293-44-8.mol
More
Less

Xipamide Chemical Properties

Melting point:
255-256 °C
Density 
1.2743 (rough estimate)
refractive index 
1.6100 (estimate)
storage temp. 
Inert atmosphere,Store in freezer, under -20°C
solubility 
DMSO: soluble20mg/mL, clear
pka
pKa 4.75±0.04(0.4% MeOH in H2O) (Uncertain)
form 
powder
color 
white to beige
Water Solubility 
58mg/L(25 ºC)
CAS DataBase Reference
14293-44-8(CAS DataBase Reference)
More
Less

Safety Information

Hazard Codes 
Xi
Risk Statements 
36/37/38
Safety Statements 
26
WGK Germany 
3
HS Code 
2935909099
More
Less

Xipamide Usage And Synthesis

Chemical Properties

Off-White Solid

Originator

Aquaphor,Beiersdorf,W. Germany ,1971

Uses

Xipamide is a diuretic and antihypertensive agent.

Definition

ChEBI: Xipamide is a member of benzamides.

Manufacturing Process

The 4-chloro-5-sulfamyl salicylic acid used as starting point was prepared in the following way:
(a) 4-Chloro-5-Chlorosulfonyl Salicylic Acid: 100 grams 4-chloro salicylic acid was added portionwise with stirring at about -5°C to 275 ml chlorosulfonic acid. The temperature was not allowed to rise above +3°C. At the end of the addition, the solution formed was stirred for 1 hour in an ice bath, then for 1 hour at 20°C and finally for 2 1/2 hours at 80°C oil bath temperature. Then the dark brown solution, after ensuing slow cooling with vigorous stirring, was poured onto ice; the precipitate was vacuum filtered, washed with water and dried. After recrystallization from toluene the compound formed had a melting point of 181° to 183°C.
(b) 4-Chloro-5-Sulfamyl Salicylic Acid: 40 grams 4-chloro-5-chlorosulfonyl salicylic acid obtained from (a) was added portionwise with stirring to 250 ml liquid ammonia. This was allowed to stand for 2 hours, then the precipitate was vacuum filtered and dissolved in 500 ml water. The solution was filtered and the filtrate was treated with 2 N hydrochloric acid until no more precipitation occurred. The 4-chloro-5-sulfamyl salicylic acid obtained as the precipitate was filtered off and finally recrystallized from water, MP 258° to 260°C.
5.0 grams 4-chloro-5-sulfamyl salicylic acid was suspended in 100 ml water- free chlorobenzene and then 2.44 grams of 2,6-dimethylaniline and 0.9 ml phosphorus trichloride were added to the suspension in turn. The reaction mixture was heated under reflux for 5 hours. After cooling, the chlorobenzene was separated from the precipitate by decantation. The latter was finally collected on a filter and washed, first with chlorobenzene and, after drying, with 2 N hydrochloric acid and water. The compound obtained by recrystallization from methanol had a melting point of 256°C.

Therapeutic Function

Diuretic, Antihypertensive

Clinical Use

Thiazide diuretic:
Hypertension
Oedema

Drug interactions

Potentially hazardous interactions with other drugs
Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect.
Anti-arrhythmics: hypokalaemia leads to increased cardiac toxicity; effects of lidocaine and mexiletine antagonised.
Antibacterials: avoid administration with lymecycline.
Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics.
Antiepileptics: increased risk of hyponatraemia with carbamazepine.
Antifungals: increased risk of hypokalaemia with amphotericin.
Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotension with postsynaptic alpha-blockers like prazosin; hypokalaemia increases risk of ventricular arrhythmias with sotalol.
Antipsychotics: hypokalaemia increases risk of ventricular arrhythmias with amisulpride; enhanced hypotensive effect with phenothiazines; hypokalaemia increases risk of ventricular arrhythmias with pimozide - avoid concomitant use.
Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias.
Cardiac glycosides: increased toxicity if hypokalaemia occurs.
Ciclosporin: increased risk of nephrotoxicity and possibly hypomagnesaemia.
Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds.
Lithium excretion reduced (increased toxicity).

Metabolism

Xipamide is excreted in the urine, partly unchanged and partly in the form of the glucuronide metabolite.
In patients with renal impairment excretion in the bile becomes more prominent.

XipamideSupplier

J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Shanghai Longsheng chemical Co.,Ltd.
Tel
021-58099652-8005 13585536065
Email
bin.wu@shlschem.com
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Jiangsu Vcare PharmaTech Co., Ltd.
Tel
13327700685
Email
sales@vcarepharmatech.com
Hangzhou Yuhao Chemical Technology Co., Ltd
Tel
0571-82693216
Email
info@yuhaochemical.com